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Purpose of the study
To evaluate prevalence and severity of hepatic steatosis
and to assess risk factors influencing liver steatosis in HIV/
HCV patients taking antiretroviral therapy (ART).
Methods
Retrospective study conducted on HIV/HCV patients
treated by ART in one clinical centre, who underwent liver
biopsies between 1995 and 2008. Hepatic steatosis was
graded according to the percentage of hepatocytes
affected: 0, none; 1, involving <33%; 2, 33–66%; and 3,
>66%. Demographics and laboratory parameters were
recorded at time of liver biopsy. Cumulative exposure to
ART was reported from the initiation of ART to liver
biopsy date. Statistical analysis was perfomed using SPSS
version 13.0.
Results
184 HIV/HCV co-infected patients were included. Median
age was 41 years (IQR, 36–45), 84% were male, 89% were
Caucasian, 61% had a past history of IV drug abuse. HCV
genotype was G1 (n = 98, 55%), G2 (10, 6%), G3 (47,
26%), and G4 (24, 13%). Median HCV-RNA was 3.18 log
KUI/ml (2.76–3.6). At the time of biopsy, median dura-
tion of HIV infection was 11 years (7–14), HIV viral load
was not detected (<200 copies/ml) in 67% of patients and
the median HIV viral load was 3.93 log copies/ml (3.15–
4.82) in patients remaining, CD4 cell count was 321/
mm3 (227–461). All patients have been exposed to NRTI,
and the median cumulative exposure was 56 months;
126, and 79, patients have received IP, and NNRTI, respec-
tively (median cumulative exposure of 23, and 16
months). Steatosis was observed in 102 patients (55%):
76 (41%) with steatosis grade 1; 10 (5%) grade 2; and 16
(9%) grade 3. By multivariate logistic regression, HCV
genotype 3 (OR, 2.6; 95%CI, 1.1–5.9), RNA HCV (OR,
2.2 per 1 log higher; 1.2–3.9), and hepatic fibrosis staging
F2-F4 (2.7; 1.4–5.5) were associated with an increased risk
of steatosis. After adjustment on period, no association
was detected between steatosis and exposure to antiretro-
viral drug classes or exposure to each drug taking sepa-
rately, or duration of exposure.
Conclusion
In our population of HIV/HCV co-infected patients receiv-
ing ART, half of them presented liver steatosis. Steatosis
was associated with genotype 3, RNA HCV, and hepatic
fibrosis. No association was observed between steatosis
and antiretroviral therapy, as well as HIV markers (i.e.
CD4 and HIV-RNA).
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P269 doi:10.1186/1758-2652-11-S1-P269
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P269
© 2008 Martinez et al; licensee BioMed Central Ltd. 
